Meeting
2021 ASCO Annual Meeting
CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Authors
Deborah J.L. Wong
University of California Los Angeles, Los Angeles, CA
Deborah J.L. Wong , Aru Panwar , Ari Rosenberg , Vidhya Karivedu , Douglas Earl Laux , Dan Paul Zandberg , Dmitri Bobilev , Luping Zhao , James Wooldridge , Art M. Krieg , Ezra E.W. Cohen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04633278
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS6089)
DOI
10.1200/JCO.2021.39.15_suppl.TPS6089
Abstract #
TPS6089
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab.
First Author: Steven Francis Powell
Poster
2023 ASCO Annual Meeting
A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
First Author: Alan Loh Ho
Poster
2023 ASCO Annual Meeting
Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.
First Author: Jared Cohen